Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07167160 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Enrollment target: 440 to 59
    • Start date changed from estimate of Jan 1, 2026 to Mar 10, 2025
    • Site details revised
    v5
  2. Trial status: Withdrawn to Not Yet Recruiting
    • Start date: Sep 1, 2025 to Jan 1, 2026
    • Enrollment target: 0 to 440
    v4
  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Not Yet Recruiting to Withdrawn Sponsor's reason: No patients enrolled
    • Enrollment target: estimated 59 to confirmed 0
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Trial Details
NCT Number NCT07167160
Lead Sponsor Women's Hospital School Of Medicine Zhejiang University
Conditions
(from sponsor)		 Cervical Cancer, Immunochemotherapy
Related terms Uterine Cervical Neoplasms
Enrollment 59 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov